Motion sickness - Symptoms, Causes, Images, and Treatment Options

Diseases

Highlights & Basics

Key Highlights

Motion sickness is a common condition provoked by transportation or visual motion.
Characterized by nausea/vomiting, possibly accompanied by other symptoms such as dizziness or headache.
Controlled breathing is helpful during episodes.
Drug therapy includes antimuscarinics and antihistamines; however both may have significant adverse effects (notably drowsiness) and impede habituation (desensitization).
Habituation and cognitive behavioral therapy may be useful for people who must undergo repeated provocative motion (e.g., for their occupations).

Quick Reference

History & Exam
- Key Factors
- Other Factors
More information...
Diagnostics Tests
More information...
Treatment Options
More information...

Definition

Epidemiology

Etiology

Pathophysiology

Citations

Key Articles

Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 8: Travel by air, land & sea - motion sickness. May 2023 [internet publication]. [Full Text]
Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.[Abstract][Full Text]

Referenced Articles

1. Stern RM, Koch KL, Andrews P. Nausea of motion sickness. In: Stern RM, Koch KL, Andrews P. Nausea: mechanisms and management. New York, NY: Oxford Press; 2011:331-353.
2. Benson AJ, Stott JR. Motion sickness. In: Rainford DJ, Gradwell DP. Ernsting's aviation medicine. 4th ed. London, UK: Hodder Arnold, Hodder Education; 2006:459-475.
3. Hu S, Grant WF, Stern RM, et al. Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviat Space Environ Med. 1991;62:308-314.[Abstract]
4. Guerraz M, Yardley L, Bertholon P, et al. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001;124:1646-1656.[Abstract][Full Text]
5. Stanney KM, Hale KS, Nahmens I, et al. What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum Factors. 2003;45:504-520.[Abstract]
6. Kennedy RS, Fowlkes JE. Simulator sickness is polygenic and polysymptomatic: implications for research. Int J Aviat Psychol. 1992;2:23-38.
7. Kennedy R, Lane N, Lilienthal M, et al. Profile analysis of simulator sickness symptoms: application to virtual reality environments. Presence. 1992;1:295-301.
8. Golding JF, Stott JR. Effect of sickness severity on habituation to repeated motion challenges in aircrew referred for airsickness treatment. Aviat Space Environ Med. 1995;66:625-630.[Abstract]
9. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 8: Travel by air, land & sea - motion sickness. May 2023 [internet publication]. [Full Text]
10. Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999;42:444-461.[Abstract]
11. Flanagan MB, May JG, Dobie TG. Sex differences in tolerance to visually-induced motion sickness. Aviat Space Environ Med. 2005;76:642-46.[Abstract]
12. Kennedy RS, Lanham DS, Massey CJ, et al. Gender differences in simulator sickness incidence: implications for military virtual reality systems. Safe J. 1995;25:69-76.
13. Klosterhalfen S, Kellermann S, Pan F, et al. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med. 2005;76:1051-1057.[Abstract]
14. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988;59:399-406.[Abstract]
15. Stern RM, Hu S, LeBlanc R, et al. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med. 1993;64: 827-830.[Abstract]
16. Golding JF, Mueller AG, Gresty MA. A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation. Aviat Space Environ Med. 2001;72:188-192.[Abstract]
17. Lawther A, Griffin MJ. Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation. J Acoust Soc Am. 1987;82:957-966.[Abstract]
18. O'Hanlon JF, McCauley ME. Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion. Aerosp Med. 1974;45:366-369.[Abstract]
19. Kennedy RS, Drexler J, Kennedy RC. Research in visually induced motion sickness. Appl Ergon. 2010;41:494-503.[Abstract]
20. Bijveld MM, Bronstein AM, Golding JF, et al. Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion. Aviat Space Environ Med. 2008;79:661-665.[Abstract]
21. Drummond PD. Triggers of motion sickness in migraine sufferers. Headache. 2005;45:653-656.[Abstract]
22. Stern RM, Koch KL, Stewart WR, et al. Spectral analysis of tachygastria recorded during motion sickness. Gastroenterol. 1987;92:92-97.[Abstract]
23. Neimer J, Eskiizmirliler S, Ventre-Dominey J, et al. Trains with a view to sickness. Curr Biol. 2001;11:R549-R550.[Abstract]
24. Williamson MJ, Thomas MJ, Stern RM. The contribution of expectations to motion sickness symptoms and gastric activity. Psychosom Res. 2004;56:721-726.[Abstract]
25. Houchens PW, Jones MB. Behavioral contagion in an experimental motion environment. Aviat Space Environ Med. 2003;74:649-653.[Abstract]
26. Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear Nose Throat J. 2006;85:25-35.[Abstract]
27. Zajonc TP, Roland PS. Vertigo and motion sickness. Part I: vestibular anatomy and physiology. Ear Nose Throat J. 2005;84:581-584.[Abstract]
28. Ventre-Dominey J, Luyat M, Denise P, et al. Motion sickness induced by otolith stimulation is correlated with otolith-induced eye movements. Neuroscience. 2008;155:771-779.[Abstract]
29. Dai M, Kunin M, Raphan T, et al. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res. 2003;151:173-189.[Abstract]
30. Cohen B, Dai M, Yakushin SB, et al. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res. 2008;171:543-553.[Abstract]
31. Stern RM, Leibowitz HW, Unblad I, et al. Tachygastria and motion sickness. Aviat Space Environ Med. 1985;56:1074-1077.[Abstract]
32. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology. 2005;65:620-622.[Abstract]
33. von Reinhart J. Histamin-intoleranz: histamin und seekrankheit. Stuttgart: Thieme; 2004.
34. Lichtenberg BK, Young LR, Arrott AP. Human ocular counterrolling induced by varying linear accelerations. Exp Brain Res. 1982;48:127-136.[Abstract]
35. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. II. VOR and perceptual responses during combined Tilt&Translation. J Neurophysiol. 2005;94:199-205.[Abstract][Full Text]
36. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. I. Frequency response of VOR and perceptual responses during Translation and Tilt. J Neurophysiol. 2005;94:186-198.[Abstract][Full Text]
37. Wood SJ. Human otolith-ocular reflexes during off-vertical axis rotation: effect of frequency on tilt-translation ambiguity and motion sickness. Neurosci Lett. 2002;323:41-44.[Abstract]
38. Money KE, Cheung BS. Another function of the inner ear: facilitation of the emetic response to poisons. Aviat Space Environ Med. 1983;54:208-211.[Abstract]
39. Treisman M. Motion sickness: an evolutionary hypothesis. Science. 1977;197:493-495.[Abstract]
40. Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1998;47:395-406.[Abstract]
41. Reavley CM, Golding JF, Cherkas LF, et al. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med. 2006 Nov;77(11):1148-52.[Abstract][Full Text]
42. Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraineurs. Brain. 2004;127:526-534.[Abstract]
43. Guerraz M, Yardley L, Bertholon P, et al. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001;124:1646-56.[Abstract][Full Text]
44. Pavlou M, Lingeswaran A, Davies RA, et al. Simulator based rehabilitation in refractory dizziness. J Neurol. 2004;251:983-95.[Abstract]
45. Golding JF, Prosyanikova O, Flynn M, et al. The effects of smoking nicotine tobacco versus smoking deprivation on motion sickness. Aviat Space Environ Med. 2008;79:262.
46. Redfern MS, Furman JM, Jacob RG. Visually induced postural sway in anxiety disorders. J Anxiety Disord. 2007;21:704-716.[Abstract][Full Text]
47. Redfern MS, Yardley L, Bronstein AM. Visual influences on balance. J Anxiety Disord. 2001;15:81-94.[Abstract]
48. Romas RT, Jacob RG, Lilienfeld SO. Space and motion discomfort in Brazilian versus American patients with anxiety disorders. J Anxiety Disord. 1997;11:131-139.[Abstract]
49. Golding JF, Kadzere P, Gresty MA. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med. 2005:76; 970-973.[Abstract]
50. Williamson MJ, Thomas MJ, Stern RM. The contribution of expectations to motion sickness symptoms and gastric activity. Psychosom Res. 2004;56:721-6.[Abstract]
51. Stern RM, Hu S, Anderson RB, et al. The effects of fixation and restricted visual field on vection-induced motion sickness. Aviat Space Environ Med. 1990;61:712-715.[Abstract]
52. Streitberger K, Ezzo J, Schneider A. Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006;129:107-17.[Abstract]
53. Hu S, Stern RM, Koch KL. Electrical acustimulation relieves vection-induced motion sickness. Gastroenterology. 1992;102:1854-8.[Abstract]
54. Denise P, Vouriot A, Normand H, et al. Effect of temporal relationship between respiration and body motion on motion sickness. Auton Neurosci. 2009;151:142-6.[Abstract]
55. Zhang LL, Wang JQ, Qi RR, et al. Motion sickness: current knowledge and recent advance. CNS Neurosci Ther. 2016 Jan;22(1):15-24.[Abstract][Full Text]
56. Golding JF. Predicting individual differences in motion sickness susceptibility by questionnaire. Pers Individ Dif. 2006;41:237-248.
57. Jokerst MD, Gatto M, Fazio R, et al. Slow deep breathing prevents the development of tachygastria and symptoms of motion sickness. Aviat Space Environ Med. 1999;70:1189-1192.[Abstract]
58. Yen Pik Sang F, Billar JP, Gresty MA, et al. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept Mot Skills. 2005;101:244-256.[Abstract]
59. Yen Pik Sang FD, Billar JP, Golding JF, et al. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med. 2003;10:108-11.[Abstract][Full Text]
60. Yen Pik Sang FD, Golding JF, Gresty MA. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviat Space Environ Med. 2003;74:998-1002.[Abstract]
61. Wood CD, Graybiel A. Evaluation of 16 antimotion sickness drugs under controlled laboratory conditions. Aerospace Med. 1968;39:1341-1344.
62. Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.[Abstract][Full Text]
63. Burton MJ, Roland PS, Rosenfeld RM. Extracts from The Cochrane Library: Scopolamine (hyoscine) for preventing and treating motion sickness. Otolaryngol Head Neck Surg. 2010;142:468-471.[Abstract]
64. Karrim N, Byrne R, Magula N, et al. Antihistamines for motion sickness. Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD012715.[Abstract][Full Text]
65. Stewart JJ, Wood MJ, Parish RC, et al. Prokinetic effects of erythromycin after antimotion sickness drugs. J Clin Pharmacol. 2000;40:347-353.[Abstract]
66. Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009;29:1082-1088.[Abstract]
67. Howland J, Rohsenow DJ, Minsky S, et al. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup Environ Health. 2008;14:250-256.[Abstract]
68. Cowings PS, Toscano WB. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. J Clin Pharmacol. 2000;40:1154-65.[Abstract]
69. Golding JF, Stott JR. Objective and subjective time courses of recovery from motion sickness assessed by repeated motion challenges. J Vestib Res. 1997;7:421-428.[Abstract]
70. Stern RM, Hu SQ, Vasey MW, et al. Adaptation to vection-induced symptoms of motion sickness. Aviat Space Environ Med. 1989 Jun;60(6):566-72.[Abstract][Full Text]
71. Ressiot E, Dolz M, Bonne L, et al. Prospective study on the efficacy of optokinetic training in the treatment of seasickness. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130:263-268.[Abstract]
72. Stroud KJ, Harm DL, Klaus DM. Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. Aviat Space Environ Med. 2005;76:352-356.[Abstract]
73. Dobie TG, May JG. Cognitive-behavioural management of motion sickness. Aviat Space Environ Med. 1994;65:C1-C2.[Abstract]
74. Toscano WB, Cowings PS. Reducing motion sickness: a comparison of autogenic-feedback training and an alternative cognitive task. Aviat Space Environ Med. 1982;53:449-453.[Abstract]
75. Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989.[Abstract]
76. Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit. 2006;12:PI1-PI7.[Abstract]
77. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain. 2011 Feb;12(1):81-8.[Abstract][Full Text]
78. Klocker N, Hanschke W, Toussaint S, et al. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci. 2001;13:227-232.[Abstract]
79. Ahmed S, Sileno AP, de Meireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000;17:974-977.[Abstract]
80. Simmons RG, Phillips JB, Lojewski RA, et al. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med. 2010;81:405-412.[Abstract]
81. Stankovic AS, Alvarenga DL, Coleman Daniels VR, et al. Intranasal scopolamine for motion sickness. Aerosp Med Hum Perform. 2019 Nov 1;90(11):917-24.[Abstract][Full Text]
82. Grunfeld E, Price C, Goadsby P, et al. Migraine, motion sickness and menstruation in mariners. Lancet. 1998;351:1106.[Abstract]